Vor Biopharma Inc. (VOR) News
Filter VOR News Items
VOR News Results
|Loading, please wait...|
VOR News Highlights
- For VOR, its 30 day story count is now at 5.
- Over the past 1 day, the trend for VOR's stories per day has been choppy and unclear. It has oscillated between 2 and 3.
Latest VOR News From Around the Web
Below are the latest news stories about Vor Biopharma Inc that investors may wish to consider to help them evaluate VOR as an investment opportunity.
Vor Biopharma Inc. (NASDAQ:VOR) price on Friday, February 11, fall -7.03% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.60. A look at the stock’s price movement, the close in the last trading session was $9.25, moving within a range at $8.35 and $9.65. Turning to its … Vor Biopharma Inc.’s (VOR) Stock Is Harder To Predict Than You Think Read More »
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences: H.C. Wainwright BioConnect 2022 Virtual Conference Presentation Date: Monday, January 10, 2022Time: Pre-recorded on-demand presentation available beginning at 7:00 AM ET 2022 B Riley Virtual Oncology ConferenceFireside Chat Live Webcast D
Vor Biopharma Inc. (NYSE:VOR) has earned an average rating of Buy from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective 
Vor Biopharma (NYSE:VOR) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Saturday, Zacks.com reports. According to Zacks, Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. 
H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage with a Buy rating on Vor Biopharma (VOR – Research Report) today and set a price target of $26.00. The company's shares closed last Thursday at $12.13, close to its 52-week low of $10.48. According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 17.0% and a 44.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Janux Therapeutics Inc, and Cellectar Biosciences. Vor Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $38.80, a 204.8% upside from current levels. In a report issued on December 2, Robert W.
No summary available.
Parametric Portfolio Associates LLC Makes New $1.60 Million Investment in Vor Biopharma Inc. (NYSE:VOR)
Parametric Portfolio Associates LLC bought a new position in Vor Biopharma Inc. (NYSE:VOR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 85,631 shares of the companys stock, valued at approximately $1,597,000. Parametric Portfolio Associates LLC owned about 0.23% of Vor Biopharma as of its most 
CAMBRIDGE, Mass., Dec. 9, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Daniella Beckman to its board of directors. Ms. Beckman, who is currently the Chief Financial Officer of Tango Therapeutics and board member for Vor Biopharma
No summary available.